



Thursday, December 11, 2025

Presentations and Posters at the San Antonio Breast Cancer Symposium

All times listed are Central Standard Time. Times and locations subject to change by SABCS.

Presentation	Speaker	Time/Location
Transcriptomic profiling of the tumor microenvironment indicates differential response to neoadjuvant chemotherapy with and without pembrolizumab in early TNBC Poster Spotlight 7: Early Triple Negative Breast Cancer—Biomarkers and Novel Approaches	Ana Garrido-Castro, MD	7 – 8:30 a.m. 302 ABC
Feasibility of a machine learning-based peripheral blood immunoprofiling platform to stratify patients with early-stage triple-negative breast cancer (eTNBC) by neoadjuvant therapy response Poster Spotlight 7: Early Triple Negative Breast Cancer—Biomarkers and Novel Approaches	Chiara Corti, MD	7 – 8:30 a.m. 302 ABC
The Genomic, Transcriptomic, and Immune Hallmarks of Metastatic Lobular Breast Cancer Poster Spotlight 9: Lobular Carcinoma	Guilherme Nader-Marta, MD	7 – 8:30 a.m. Hemisfair 1-2
Poster Spotlight 9: Lobular Carcinoma	Otto Metzger, MD Discussant: Clinical	7 – 8:30 a.m. Hemisfair 1-2
Weight Trajectories in the Breast Cancer Weight Loss (BWEL) Trial (Alliance) Poster Spotlight 8: Beyond the Scale—Obesity and GLP-1 Therapies in Breast Cancer	Chao Cao, PhD	7 – 8:30 a.m. 221 ABC
Ultrasensitive ctDNA Tracking Predicts Exceptional Response in HER2+ Metastatic Breast Cancer Poster Spotlight 5: Liquid Biomarkers in Breast Cancer—Driving Precision Medicine	Stefania Morganti, MD	7 – 8:30 a.m. Hemisfair 3
Treatment updates in metastatic TNBC Educational Session 11: How to Treat TNBC—Triple-Negative Not so Negative Anymore	Sara Tolaney, MD, MPH	2:30 – 4:15 p.m. Stars at Night 1-2

Continued >





Thursday, December 11, 2025

Why: Molecular and immunological basis of breast cancer across the age continuum

Kornelia Polyak, MD, PhD

2:30 – 4:15 p.m.
Hemisfair 3

Educational Session 14: Breast Cancer in Young Women—When, Why, and How?

Central Nervous System Outcomes from the Phase III PATINA Trial (AFT-38)

Otto Metzger, MD

4:30 – 5:30 p.m.
Stars at Night 1-2

Rapid Fire 4

Poster Session 3

12:30 – 2 p.m. | Exhibit Hall

Poster	Presenter
PS3-01-25: Replication stress as a driver of breast tumorigenesis in BRCA1 heterozygous carrier derived breast organoids	Ozge Somuncu, PhD
PS3-04-23: Artificial intelligence (AI)-generated electronic medical record summarization in breast oncology	Ko Un Park, MD
PS3-07-09: Extended Endocrine Therapy (eET) Following Five Years of Adjuvant LHRH-agonist (LHRHa) in Premenopausal Patients with Node-Positive, Hormone Receptor (HR)-Positive early Breast Cancer (eBC): a subanalysis according to surrogate subtypes	Carmine Valenza, MD, MPH
PS3-08-13: Exploratory analysis of palbociclib benefit in the PALLAS trial by SETERPR index and prior chemotherapy regimens (ABCSG-42/AFT-05/BIG-14-13)	Otto Metzger, MD
PS3-08-29: Retrospective study evaluating eligibility, treatment patterns, and clinicopathologic factors associated with adjuvant abemaciclib use in patients with high-risk estrogen receptor-positive (ER+) HER2-negative (HER2-) early breast cancer (EBC)	Chiara Corti, MD
PS3-11-04: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients with HER2+ Breast Cancer – Results from the ATOP Study	Rachel A. Freedman, MD, MPH
PS3-11-06: Long-term prognostic and predictive value of lobular histology in the PALLAS trial	Guilherme Nader-Marta, MD
PS3-11-28: EmpowHER-208: A phase 2 neoadjuvant study of zanidatamab in combination with chemotherapy in patients with stage II-III HER2-positive early breast cancer	Adrienne G. Waks, MD
PS3-12-01: T-cell receptor (TCR) Repertoire Differences Between Stage III Inflammatory Breast Cancer (IBC) and Matched Non-IBC Controls	Ilana Schlam, MD, MPH
PS3-12-15: Mapping the imprint of taxane chemotherapy on the metastatic microenvironment in HR+ breast cancer with single cell and spatial profiling	Daniel Abravanel, MD, PhD

Continued >



Thursday, December 11, 2025

Poster Session 4

5 – 6:30 p.m. | Exhibit Hall

Poster	Presenter
PS4-07-25: Real World Analysis of Efficacy, Toxicity, and Treatment Patterns of Pembrolizumab-Containing Regimens for Older Adults with Early-Stage Triple Negative Breast Cancer	Claire Smith, MD
PS4-09-25: Variation in diagnostic imaging features of breast cancer by race and ethnicity	Ashley Odai-Afotey, MD
PS4-09-29: Variation in weight loss and intervention engagement in the Breast Cancer Weight Loss (BWEL) trial by language and ethnicity (Alliance)	Ashley Odai-Afotey, MD